title: Impact of concurrent chemotherapy on definitive radiotherapy for women with FIGO IIIb cervical cancer.
abstract: The purpose of this retrospective study is to investigate the impact of concurrent chemotherapy on definitive radiotherapy for the International Federation of Gynecology and Obstetrics (FIGO) IIIb cervical cancer. Between 2000 and 2009, 131 women with FIGO IIIb cervical cancer were treated by definitive radiotherapy (i.e. whole pelvic external beam radiotherapy for 40-60 Gy in 20-30 fractions with or without center shielding and concomitant high-dose rate intracavitary brachytherapy with 192-iridium remote after loading system for 6 Gy to point A of the Manchester method). The concurrent chemotherapy regimen was cisplatin (40 mg/m(2)/week). After a median follow-up period of 44.0 months (range 4.2-114.9 months) and 62.1 months for live patients, the five-year overall survival (OS), loco-regional control (LRC) and distant metastasis-free survival (DMFS) rates were 52.4, 80.1 and 59.9%, respectively. Univariate and multivariate analyses revealed that lack of concurrent chemotherapy was the most significant factor leading to poor prognosis for OS (HR = 2.53; 95% CI 1.44-4.47; P = 0.001) and DMFS (HR = 2.53; 95% CI 1.39-4.61; P = 0.002), but not for LRC (HR = 1.57; 95% CI 0.64-3.88; P = 0.322). The cumulative incidence rates of late rectal complications after definitive radiotherapy were not significantly different with or without concurrent chemotherapy (any grade at five years 23.9 vs 21.7%; P = 0.669). In conclusion, concurrent chemotherapy is valuable in definitive radiotherapy for Japanese women with FIGO IIIb cervical cancer.
authors: Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan. yuuki.kuroda.96@gmail.com
authors: Yuuki
authors: Y
authors: Kuroda
authors: Naoya
authors: N
authors: Murakami
authors: Madoka
authors: M
authors: Morota
authors: Shuhei
authors: S
authors: Sekii
authors: Kana
authors: K
authors: Takahashi
authors: Koji
authors: K
authors: Inaba
authors: Hiroshi
authors: H
authors: Mayahara
authors: Yoshinori
authors: Y
authors: Ito
authors: Ryo-Ichi
authors: R
authors: Yoshimura
authors: Minako
authors: M
authors: Sumi
authors: Yoshikazu
authors: Y
authors: Kagami
authors: Noriyuki
authors: N
authors: Katsumata
authors: Takahiro
authors: T
authors: Kasamatsu
authors: Jun
authors: J
authors: Itami
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D059248:Chemoradiotherapy / Q000379:methods; D003131:Combined Modality Therapy / Q000379:methods; D004307:Dose-Response Relationship, Radiation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007564:Japan; D008495:Medical Oncology / Q000379:methods; D008875:Middle Aged; D015233:Models, Statistical; D011379:Prognosis; D012189:Retrospective Studies; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*
chemical_list: D000970:Antineoplastic Agents